Extracorporeal membrane oxygenation technology for adults: an evidence mapping based on systematic reviews
ConclusionsThere is limited available evidence for ECMO that large sample, multi-center, and multinational RCTs are needed. Most clinical topics are reported as beneficial or probably beneficial of SRs for ECMO. Evidence mapping is a valuable and reliable methodology to identify and present the existing evidence about therapeutic interventions. (Source: European Journal of Medical Research)
Source: European Journal of Medical Research - April 22, 2024 Category: Research Source Type: research
Lower airway microbiota compositions differ between influenza, COVID-19 and bacteria-related acute respiratory distress syndromes
Acute respiratory distress syndrome (ARDS) is responsible for 400,000 deaths annually worldwide. Few improvements have been made despite five decades of research, partially because ARDS is a highly heterogeneo... (Source: Critical Care)
Source: Critical Care - April 22, 2024 Category: Intensive Care Authors: S ébastien Imbert, Mathilde Revers, Raphaël Enaud, Arthur Orieux, Adrian Camino, Alexandre Massri, Laurent Villeneuve, Cédric Carrié, Laurent Petit, Alexandre Boyer, Patrick Berger, Didier Gruson, Laurence Delhaes and Renaud Prével Tags: Brief Report Source Type: research
A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice
In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This ...
Source: Virus Research - April 21, 2024 Category: Virology Authors: Zhenfei Wang Weiyang Sun Dongxu Li Yue Sun Menghan Zhu Wenqi Wang Yiming Zhang Entao Li Feihu Yan Tiecheng Wang Na Feng Songtao Yang Xianzhu Xia Yuwei Gao Source Type: research
A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice
In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This ...
Source: Virus Research - April 21, 2024 Category: Virology Authors: Zhenfei Wang Weiyang Sun Dongxu Li Yue Sun Menghan Zhu Wenqi Wang Yiming Zhang Entao Li Feihu Yan Tiecheng Wang Na Feng Songtao Yang Xianzhu Xia Yuwei Gao Source Type: research
Isolation and genetic characterization of multiple genotypes of both H5 and H7 avian influenza viruses from environmental water in the Izumi plain, Kagoshima prefecture, Japan during the 2021/22 winter season
This study underscores the importance of monitoring both HPAIVs and LPAIVs to understand avian influenza virus ecology in migratory waterfowl populations.PMID:38640701 | DOI:10.1016/j.cimid.2024.102182 (Source: Comparative immunology, microbiology and infectious diseases.)
Source: Comparative immunology, microbiology and infectious diseases. - April 19, 2024 Category: Allergy & Immunology Authors: Kosuke Okuya Mana Esaki Kaori Tokorozaki Taichi Hasegawa Makoto Ozawa Source Type: research
Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken
This study investigated H9- and ND-specific humoral and mucosal responses, H9-specific cell-mediated immunity, and protection conferred by the rHVT-H9-F vaccine in specific pathogen-free (SPF) chickens. Vaccination elicited systemic NDV F- and AIV H9-specific antibody response but also local antibodies in eye wash fluid and oropharyngeal swabs. The ex vivo H9-specific stimulation of splenic and pulmonary T cells in the vaccinated group demonstrated the ability of vaccination to induce systemic and local cellular responses. The clinical protection against a challenge using a LPAIV H9N2 strain of the G1 lineage isolated in M...
Source: Vaccine - April 19, 2024 Category: Allergy & Immunology Authors: Fiona Ingrao Eva Ngabirano Fabienne Rauw Gwena ëlle Dauphin B énédicte Lambrecht Source Type: research
Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
CONCLUSIONS: Concomitant administration of PPSV-23 and influenza vaccine in the elderly was not associated with a higher risk of most prespecified adverse events (AEs) compared to sequential vaccination. This study supports the safety of concomitant administration of PPSV-23 and influenza vaccine.PMID:38641496 | DOI:10.1016/j.vaccine.2024.03.078 (Source: Vaccine)
Source: Vaccine - April 19, 2024 Category: Allergy & Immunology Authors: Heehyun Won Jeong Ah Kim Na-Young Jeong Nam-Kyong Choi Source Type: research
The global impact of SARS-CoV-2 variant BA.2.86: a comprehensive analysis with the latest developments and transmission trends - an epidemiological study
CONCLUSIONS: The SARS-CoV-2, novel variant BA.2.86, spread over six continents and 89 countries and affected 19,532 people worldwide. The disease is more prevalent in the United Kingdom, United States of America, and European countries. The detection of the disease in multiple continents and countries suggests some degree of transmissibility. Global health authorities need to rethink their policies and implement strict strategies to eradicate emerging variants and minimize the global disease burden.PMID:38639533 | DOI:10.26355/eurrev_202404_35928 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 19, 2024 Category: Drugs & Pharmacology Authors: S A Meo A S Meo D M Halepoto Source Type: research
Evolution and Antigenic Differentiation of Avian Influenza A(H7N9) Virus, China
Emerg Infect Dis. 2024 Apr 19;30(6). doi: 10.3201/eid3006.230530. Online ahead of print.ABSTRACTWe characterized the evolution and molecular characteristics of avian influenza A(H7N9) viruses isolated in China during 2021-2023. We systematically analyzed the 10-year evolution of the hemagglutinin gene to determine the evolutionary branch. Our results showed recent antigenic drift, providing crucial clues for updating the H7N9 vaccine and disease prevention and control.PMID:38640498 | DOI:10.3201/eid3006.230530 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 19, 2024 Category: Infectious Diseases Authors: Yang Liu Yuhua Chen Zhiyi Yang Yaozhong Lin Siyuan Fu Junhong Chen Lingyu Xu Tengfei Liu Beibei Niu Qiuhong Huang Haixia Liu Chaofeng Zheng Ming Liao Weixin Jia Source Type: research
The global impact of SARS-CoV-2 variant BA.2.86: a comprehensive analysis with the latest developments and transmission trends - an epidemiological study
CONCLUSIONS: The SARS-CoV-2, novel variant BA.2.86, spread over six continents and 89 countries and affected 19,532 people worldwide. The disease is more prevalent in the United Kingdom, United States of America, and European countries. The detection of the disease in multiple continents and countries suggests some degree of transmissibility. Global health authorities need to rethink their policies and implement strict strategies to eradicate emerging variants and minimize the global disease burden.PMID:38639533 | DOI:10.26355/eurrev_202404_35928 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 19, 2024 Category: Drugs & Pharmacology Authors: S A Meo A S Meo D M Halepoto Source Type: research
Evolution and Antigenic Differentiation of Avian Influenza A(H7N9) Virus, China
Emerg Infect Dis. 2024 Apr 19;30(6). doi: 10.3201/eid3006.230530. Online ahead of print.ABSTRACTWe characterized the evolution and molecular characteristics of avian influenza A(H7N9) viruses isolated in China during 2021-2023. We systematically analyzed the 10-year evolution of the hemagglutinin gene to determine the evolutionary branch. Our results showed recent antigenic drift, providing crucial clues for updating the H7N9 vaccine and disease prevention and control.PMID:38640498 | DOI:10.3201/eid3006.230530 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 19, 2024 Category: Infectious Diseases Authors: Yang Liu Yuhua Chen Zhiyi Yang Yaozhong Lin Siyuan Fu Junhong Chen Lingyu Xu Tengfei Liu Beibei Niu Qiuhong Huang Haixia Liu Chaofeng Zheng Ming Liao Weixin Jia Source Type: research
The global impact of SARS-CoV-2 variant BA.2.86: a comprehensive analysis with the latest developments and transmission trends - an epidemiological study
CONCLUSIONS: The SARS-CoV-2, novel variant BA.2.86, spread over six continents and 89 countries and affected 19,532 people worldwide. The disease is more prevalent in the United Kingdom, United States of America, and European countries. The detection of the disease in multiple continents and countries suggests some degree of transmissibility. Global health authorities need to rethink their policies and implement strict strategies to eradicate emerging variants and minimize the global disease burden.PMID:38639533 | DOI:10.26355/eurrev_202404_35928 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 19, 2024 Category: Drugs & Pharmacology Authors: S A Meo A S Meo D M Halepoto Source Type: research
Evolution and Antigenic Differentiation of Avian Influenza A(H7N9) Virus, China
Emerg Infect Dis. 2024 Apr 19;30(6). doi: 10.3201/eid3006.230530. Online ahead of print.ABSTRACTWe characterized the evolution and molecular characteristics of avian influenza A(H7N9) viruses isolated in China during 2021-2023. We systematically analyzed the 10-year evolution of the hemagglutinin gene to determine the evolutionary branch. Our results showed recent antigenic drift, providing crucial clues for updating the H7N9 vaccine and disease prevention and control.PMID:38640498 | DOI:10.3201/eid3006.230530 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - April 19, 2024 Category: Infectious Diseases Authors: Yang Liu Yuhua Chen Zhiyi Yang Yaozhong Lin Siyuan Fu Junhong Chen Lingyu Xu Tengfei Liu Beibei Niu Qiuhong Huang Haixia Liu Chaofeng Zheng Ming Liao Weixin Jia Source Type: research
The global impact of SARS-CoV-2 variant BA.2.86: a comprehensive analysis with the latest developments and transmission trends - an epidemiological study
CONCLUSIONS: The SARS-CoV-2, novel variant BA.2.86, spread over six continents and 89 countries and affected 19,532 people worldwide. The disease is more prevalent in the United Kingdom, United States of America, and European countries. The detection of the disease in multiple continents and countries suggests some degree of transmissibility. Global health authorities need to rethink their policies and implement strict strategies to eradicate emerging variants and minimize the global disease burden.PMID:38639533 | DOI:10.26355/eurrev_202404_35928 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 19, 2024 Category: Drugs & Pharmacology Authors: S A Meo A S Meo D M Halepoto Source Type: research
